Moxiclav BIS Indications/Uses

Moxiclav Bis should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data.
Moxiclav Bis suspension for twice daily oral dosing, is indicated for short term treatment of bacterial infections at the following sites when amoxicillin resistant beta-lactamase producing strains are suspected as the cause. In other situations, amoxicillin alone should be considered.
Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia.
Urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
Skin and soft tissue infections e.g. cellulitis, animal bites.
Susceptibility to Moxiclav Bis will vary with geography and time.
Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
Mixed infections caused by amoxicillin-susceptible organisms in conjunction with Moxiclav Bis susceptible beta-lactamase producing organisms may be treated with Moxiclav Bis suspension 457 mg/5 ml. These infections should not require the addition of another antibiotic resistant to beta-lactamases.